An analysis of fecal occult blood testing to screen for colorectal cancer linked the diagnostic to long-term reduced cancer-related mortality. Dr. Aasma Shaukat of the Minneapolis VA Medical Center discussed the findings at the ACG Annual Scientific Meeting, noting a 32% reduction in CRC mortality seen with annual screening in the Minnesota Fecal Occult Blood Trial may be credited to patients who tested positive on the FOBT and had a follow-up colonoscopy and polypectomy. The current study involves a 30-year follow-up on the Minnesota trial, previously analyzed with 18-year follow-up.

Related Summaries